Abstract
Beta-amyloid (Aβ) is an important factor in the development of pathology in Alzheimer’s disease. Level of beta-amyloid precursor protein (APP) is increased in neurites with age and in Alzheimer’s disease model mice. However, it is unclear whether Aβ can affect APP levels in cells. The aim of this study was to evaluate the effect of Aβ on the level and trafficking of APP in human neuroblastoma cells and to identify the role of cardiotonic steroid (CTS) ouabain in this process. Western blot analysis revealed that 30-min incubation of the cells with 100 nM Aβ increased APP levels by 75%. Confocal microscopy showed that Aβ alters APP trafficking, promoting its movement into neurites. This effect establishes a positive feedback loop that accelerates Aβ formation in neurites. The rise in APP was associated with Src kinase activation triggered by Aβ binding to Na,K-ATPase. Notably, Src kinase inhibition completely blocked the Aβ-induced increase in APP, indicating that beta-amyloid effect on APP is mediated by Src kinase activation. Furthermore, 100 nM CTS ouabain, a specific Na,K-ATPase ligand, significantly decreased Aβ′s impact on APP and Src kinase activation. Given that CTS are naturally present in the human body, these findings are important for developing therapeutic strategies to counteract Aβ-driven APP accumulation and for understanding the role of endogenous CTS in regulating Aβ formation.
Introduction
Beta-amyloid peptide (Aβ), and mutations that lead to its accelerated oligomerization are the key to the onset of Alzheimer’s disease (AD), one of the most common neurodegenerative diseases (; ; ). This disease leads to synapse loss, neuronal dysfunction and death, causing progressive dementia accompanied by the formation of amyloid plaques in the brain (). The risk of the emergence of AD increases with age ().
Aβ is produced from beta-amyloid precursor protein (APP) by β-site APP-cleaving enzyme 1 (BACE1) and gamma-secretase (). Membrane trafficking of APP and BACE 1 determines the probability of their contact and consequently the rate of Aβ production (). In neuronal cells, the interaction between APP and BACE1 has been detected in the cytoplasmic membrane, endoplasmic reticulum (ER), trans-Golgi network, and endosomes (). APP is represented in all parts of the neuronal cell including soma, axons, dendrites, and synaptic sites (). From the trans-Golgi network, APP is transported to the cytoplasmic membrane (), where it is processed through either a non-amyloidogenic pathway, which leads to the formation of the neuroprotective soluble APP (after cleavage by α-secretase and γ-secretase) (), or an amyloidogenic pathway, which results in Aβ formation (after cleavage by BACE1 and gamma-secretase).
Aβ is secreted pre- and postsynaptically () and then binds to the post- or presynaptic membrane, being further captured to the cell by endocytosis. Accumulation and oligomerization of Aβ affects synaptic plasticity (). On the membrane surface of neuronal cells, Aβ binds several proteins (). One important target of Aβ is Na,K-ATPase (), which creates the sodium-potassium gradient crucial for neuronal viability and functionality. In Alzheimer’s disease, a steady decrease in Na,K-ATPase activity is observed (; ; ). This is caused by Aβ binding () and subsequent oligomerization on the Na,K-ATPase (). Particularly, we have previously shown that a monomer of Aβ acts as a ligand of Na,K-ATPase that, being bound, induces the activation of Src kinase (). Since Src kinase, in its turn, regulates APP trafficking by phosphorylating Munc-18–1 interacting protein (Mint) (), we hypothesized () that Aβ may also influence the trafficking of its precursor protein by creating a positive feedback loop via Src kinase activation.
Aβ accumulation has been shown in the aging brain (; ; ). Additionally, it is shown that APP processing also increases with age (). Presumably, this happens due to altered APP trafficking in aging neurons (). In murine cortical senescent neurons, disturbed APP trafficking has been shown in vitro and in vivo. As a result, APP accumulates in neurites with age (). However, until now, it has not been determined whether Aβ can directly affect APP content and transport.
In the present study, we demonstrated on SY-SY5Y human neuroblastoma cells that Aβ42 leads to an increase in the total level of APP and its accumulation in the neurites of the cells. Since cardiotonic steroid ouabain is a specific ligand of Na,K-ATPase () that is also able to induce the activation of Na,K-ATPase-associated Src kinase (for review see ; ), ouabain was presumed to modulate the action of Aβ42 on Src kinase activation. Ouabain-like factor is present in cerebrospinal fluid () and is produced directly in the brain (). Acute binding of ouabain to Na,K-ATPase does not affect its binding to Aβ42 (), it is reasonable to suggest that this ligand may bind Na,K-ATPase simultaneously with Aβ42, influencing the cellular response to Aβ42. We characterized the effect of ouabain on Aβ42-induced changes in APP level and proved its ability to attenuate APP accumulation induced by Aβ42.
Materials and methods
Cell line
Human neuroblastoma cell line SH-SY5Y obtained from the American Type Culture Collection was cultured in RPMI-1640 medium (Gibco, ThermoFisher Scientific, Waltham, MA, United States), containing 10% fetal bovine serum (FBS; Gibco, ThermoFisher Scientific, MA, United States), 100 units/mL penicillin, 100 μg/mL streptomycin, pyruvate and glutamax (Gibco, ThermoFisher Scientific, Waltham, MA, United States). Culture maintenance was performed in cultural flasks T-25 and T-75 at 37 °C in humid atmosphere, containing 5% CO2. SH-SY5Y cells were dissociated via washing with Versene solution (Gibco, ThermoFisher Scientific, Waltham, MA, United States) and 0.05% trypsin-EDTA (Gibco, ThermoFisher Scientific, Waltham, MA, United States) digestion at 37 °C during 5 min. Passages did not exceed 15. For confocal microscopy cells were seeded on 35 mm glass-based Petri dishes (Nunc, Rochester, NY, United States, 150680) in a quantity 15000 per dish. For Western blotting, redox parameters and Ca2+ level measurements SH-SY5Y cells were grown on 6- and 12-well plates until 80%–90% confluency was achieved.
Aβ42 preparation
Synthetic peptide Aβ42: [H2N]-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-[COOH] was obtained from Biopeptide (San Diego, CA, United States). Preparation of the monomeric form of Aβ42 was performed as described elsewhere. Cold hexafluoroisopropanol (Fluka) was added to dry Aβ42 until peptide concentration 1 mM was achieved. After 1 h incubation peptide solution was transferred on ice for 10 min and aliquoted into microcentrifuge tubes (0.56 mg Аβ42 per tube). Aliquots were dried under vacuum using Eppendorf Concentrator 5301. Dried peptide films were stored at −80 °C. 2.5 mM stock solution was prepared by dissolving 0.22 mg of dry peptide in 20 μL of 100% anhydrous DMSO (Sigma-Aldrich, St. Louis, MO, United States) and 1-h incubation. The required concentration of Aβ42 was achieved by dilution of stock solution with RPMI-1640 medium or Tyrode solution. An equivalent volume of pure DMSO was added to control probes. Only fresh-dissolved Aβ42 was used in experiments.
Aβ42 and ouabain treatment
Incubation of SH-SY5Y cells on plates or dishes with amyloid peptide required medium replacement with FBS-free RPMI-1640. For the flow cytometry studies SH-SY5Y сells were dissociated and suspended in Tyrode solution with following staining before incubations with ouabain and Aβ42. Aβ42 stock solution was diluted and added to samples in final concentration 100 nM. Beta-amyloid effects was studied by SH-SY5Y incubation for 30 min. Influence of ouabain or Src kinase inhibitor 1 (SRCI1) was estimated by pre-treatment with single compounds for 30 min before adding of Aβ42 solution. Ouabain (Fluka) was used in 100 nM concentration, SRCI1 – 10 μM. All incubations were performed at 37 °C in humid atmosphere, containing 5% CO2.
Amyloid precursor protein distribution studies
SH-SY5Y cells were cultured on Petri dishes until 50% confluency was achieved. Medium was replaced with FBS-free RPMI-1640 and cells were incubated with 100 nM Aβ42 during 15–240 min. For each time point own control without addition of Aβ42 was performed. As incubations ended cells were washed with ice-cold Ca2+/Mg2+ PBS and fixed in 4% para-formaldehyde solution for 10 min. At the end of fixation cells were washed with Ca2+/Mg2+ PBS and treated with monoclonal rabbit antibodies against N-terminal extracellular domain of amyloid precursor protein (dilution in PBS to the concentration 3.84 μg/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab126732) at 4 °C overnight. Next day, samples were washed with Ca2+/Mg2+ PBS and incubated for 2 h at room temperature with secondary antibodies, conjugated with AlexaFluor® 488 (Ex/Em = 495/519 nm, dilution in PBS to the concentration 4 μg/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab150077). Before the imaging nuclei were stained with NucBlue™ (Hoechst 33342) (Ex/Em = 360/460, Invitrogen, ThermoFisher Scientific, MA, United States, R37605) in accordance with the manufacturer’s protocol.
Laser scanning confocal microscopy
The attached and stained SH-SY5Y cells in the 35 mm glass-based Petri dishes were covered with Ca2+/Mg2+ PBS and imaged using a confocal microscope Leica TCS SP5 (Leica, Wetzlar, Germany). APP was labeled with AlexaFluor® 488-conjugated antibodies and imaged using a 488 nm argon laser. Nuclei were stained with NucBlue™ (Hoechst 33342) and visualized with 405 nm diode laser. The resulting images were analyzed using LAS X imaging software (Leica, Wetzlar, Germany). Received images were analyzed using ImageJ 1.54 g (Wayne Rasband and contributors, National Institutes of health, United States). The fluorescence ratio between neurites and cell bodies was calculated, value of every single time measurement was normalized to control with the same time of incubation.
Estimation of APP levels and Src kinase activation
Cells were grown on 6- and 12-well plates until 80%–90% confluency was achieved. Medium was replaced with FBS-free RPMI-1640 and cells were incubated with Aβ42, cardiotonic steroids and Src kinase inhibitor 1. After the ending of incubation wells were washed with Ca2+/Mg2+ PBS and cells were lysed with RIPA-buffer (ThermoFisher Scientific, Waltham, MA, United States, 89900), containing protease inhibitors cocktail (Roche, 11836145001), phosphatase inhibitors cocktail (Roche, 4906837001), 0.2 mM PMSF and 5 μM thiorphan (Cayman Chemical, Ann Arbor, MI, United States, 15600), with stirring for an hour at 4 °C. Lysates were centrifuged at 4 °C and 16000 g for 10 min and supernatants were collected.
The cell lysates were separated via 10% SDS-PAGE electrophoresis and transferred to a PVDF-membrane (Bio-Rad, Hercules, CA, United States, 1620137). Membranes were blocked in 5% nonfat milk in TBST (50 mM Tis-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) for an hour and were incubated with monoclonal primary rabbit antibodies specific to APP (dilution in 5% milk-TBST to the concentration 76,8 ng/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab32136), β-actin (dilution in TBST to the concentration 60 ng/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab8227), Src kinase (dilution in 5% milk-TBST to the concentration 67 ng/mL, Cell Signaling Technology, Danvers, MA, United States, 2108S) and Phospho-Src Family (Tyr416) (dilution in 5% milk-TBST to the concentration 51 ng/mL, Cell Signaling Technology, Danvers, MA, United States, 6943S) overnight at 4 °C. Then, the membranes were washed in TBST and incubated with goat anti-rabbit secondary antibodies, conjugated with HRP (dilution in TBST to the concentration 140 ng/mL, HyTest, Moscow, Russia, GARC). Imaging of the membranes was performed using SuperSignal™ West Femto Maximum Sensitivity Substrate kit (ThermoFisher Scientific, MA, United States, 34096) and Bio-Rad ChemiDoc MP instrument (Bio-Rad, Hercules, CA, United States). Densitometric analysis was performed with Image Lab 6.0.1 program (Bio-Rad, Hercules, CA, United States). Results were expressed as APP levels, normalized on that in control (APP, %), or phospho-Src/Src ratio (p-Src/Src, fold change).
Assessment of Ca2+ levels, mitochondrial potential and redox status of the cells
SH-SY5Y cells were grown on 12-well plates at 37 °C in humid atmosphere, containing 5% CO2, and suspended in Tyrode solution after achieving 80%–90% confluency. Then, suspensions from every well were divided into two parts, every sample was stained simultaneously with GSH- and Ca2+-specific or ROS- and mitochondrial membrane potential-specific dyes. The ROS level was assessed using the dihydrorodamine 123 (DHR) dye (Ex/Em = 488/525 nm; Invitrogen, ThermoFisher Scientific, MA, United States, D23806, used in a concentration 5 μM). Assessment of the Ca2+ level was performed by staining with fluo-4, AM (Ex/Em = 494/506 nm; Invitrogen, ThermoFisher Scientific, MA, United States, F14201). The monobromobimane dye (Ex/Em = 393/490 nm, Sigma-Aldrich, St. Louis, MO, B4380, used in a concentration 20 μM) was used for the reduced glutathione (GSH) staining. The mitochondrial potential was assessed using the MitoProbe™ DiIC1(5) Assay Kit (Ex/Em = 638/658 nm; Invitrogen, ThermoFisher Scientific, MA, United States, M34151, used in a concentration 50 nM). All parameters were recorded for the cells with intact membrane. The dyes were incubated at 37 °C for 30 min. Detection of the cells with damaged membrane (dead cells) was performed by staining with propidium iodide (PI) (Ex/Em = 535/617 nm, Sigma-Aldrich, St. Louis, MO, P4170, used in a concentration 10 μg/mL) 1 minute before measurement. When assessing the levels of ROS, GSH and mitochondrial potential, dead cells were excluded from consideration. The cells were analyzed using a flow cytometer BD LSR Fortessa (Becton Dickinson, Franklin Lakes, NJ, United States).
Statistical analysis
All experimental data are shown as mean values ± standard deviations of mean (SD), with the number of independent experiments (n) indicated in Figure legends. The statistical difference between experimental groups was analyzed by one-way ANOVA with Tukey correction for multiple comparisons. Probability values (p) less than 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism 9.1.2 software (GraphPad Software Inc., San Diego, CA, United States).
Results
Аβ42 increases APP level and alters its distribution in SH-SY5Y cells
Western blot analysis revealed that 30-min of incubation with 100 nM Аβ42 causes significant increase in APP level in SH-SY-5Y cells by 75% (Figures 1A,B). Using confocal microscopy, we evaluated the change of fluorescence level in neurites relative to the cell body after 15, 30 min, 1, 2 and 4 h of incubation with 100 nM Aβ42 (Figures 1C,D). In cells untreated with primary antibodies to APP signal was not detected (Supplementary Figure S1). Relative fluorescence in neurites after 1 hour of incubation is higher than after 15 min of incubation with Aβ42. After 2 h of Aβ42 exposure, the relative fluorescence is significantly increased compared to the control cells. After 4 h, the relative fluorescence in neurites already exceeds this value in the control cells by 1.5 times. All in all, Аβ42 induces the increase in APP level and its latter accumulation on the surface of neurites.
FIGURE 1
Src kinase mediates Aβ42-dependent APP accumulation in a redox-independent way
According to the data obtained in our previous studies (), Aβ42 induces Src kinase activation in SH-SY5Y cells. Treatment by100 nM Aβ42 increased APP level in cells by 75%, whereas 10 μM Src inhibitor (SRCI1) pre-treatment completely prevented this effect (Figures 2A,B). Notably, the inhibitor itself did not affect APP accumulation. Src kinase activation in these probes was evaluated as a ratio of phosphorylated at Y419 Src kinase (p-Src) to total Src kinase signals. SRCI1 decreases Src activation in cells and prevents its growth after Aβ42 treatment (Figures 2C,D). The obtained data show that Src kinase activation has a crucial role in the Aβ42-mediated gain of APP accumulation.
FIGURE 2
Earlier, we demonstrated that incubation with Aβ42 during 30 min declines GSH and ROS levels in SH-SY5Y cells (). This change in redox status is not associated with changes in calcium and mitochondrial potential (Supplementary Figure S2). To find out whether the observed change in redox status of cells is associated with Src kinase activation and altered APP trafficking, we added Src kinase inhibitor to the cells that were further exposed to Аβ42, and evaluated whether the inhibition of Src kinase affected the Aβ42 -induced changes in GSH (Figure 2E). The 30-min pre-treatment with 10 mM SRCI1 before exposing to 100 nM Aβ42 does not prevent Aβ42-induced changes in GSH levels, suggesting that the reduced glutathione decrease in the presence of Аβ42 is achieved by mechanisms that do not imply Src kinase activation. Also, it does not change the effect of Aβ42 on ROS level (Supplementary Figure S3). Therefore, Aβ42-induced increase in APP level does not depend on the redox status of cells.
Ouabain diminishes Aβ42-mediated amplification of APP level
Activation of Src kinase is induced by the interaction of Aβ42 with Na,K-ATPase (). Earlier, we demonstrated that CTS ouabain binding to Na,K-ATPase does not affect its binding to Aβ42 (). Therefore, we presumed that ouabain can modulate effects caused by Аβ42 via Na,K-ATPase. To study the potential ability of ouabain to modulate the effect of Aβ42 on neuronal cells, we performed a series of experiments with 100 nM ouabain, which is equimolar to Aβ42. At this concentration, ouabain does not exert a toxic effect on the cells (Supplementary Figure S4).
Treatment of cells with 100 nM ouabain for 30 min does not alter APP accumulation (Figures 3A,B). Adding of Aβ42 after ouabain pre-treatment prevents the Aβ42- induced increase in APP level (Figures 3A,B). Thereby, ouabain blocks the effect of Aβ42 on APP level and prevents the accumulation of APP in SH-SY5Y cells.
FIGURE 3
Ouabain prevents Aβ42-induced Src kinase activation
The signaling cascade via Src kinase seems to be a key mechanism of the APP level amplification caused by Aβ42 (Figure 2). Ouabain affects Src kinase-dependent and Src-independent signaling pathways (; ; ). That is why we found it important to define the impact of ouabain on Src kinase activation.
30-min incubation of SH-SY5Y cells with 100 nM ouabain does not induce Src kinase activation. Moreover, ouabain prevents Src activation by Aβ42 (Figures 3C,D). These data are in a good agreement with the results described above (Figures 3A,B).
Discussion
It has been previously suggested that altered trafficking of APP in aging neurons and its accumulation in neurites with age (), accompanied by its intensified processing (), may be responsible for the observed age-dependent increase in brain Aβ levels (; ; ). Moreover, APP accumulation in neurites has been described in animal models of AD (). Still, it was unclear whether a feedback loop between Aβ and its precursor protein exists and whether increasing levels of Aβ can influence APP protein level and trafficking.
In this study, we found that Aβ42 stimulates the increase in APP level and its accumulation in neurites in human neuroblastoma SH-SY5Y cells. As local accumulation of APP sets off its amyloidogenic procession, our findings suggest the existence of a positive feedback loop via Src-kinase activation that enhances the Aβ formation. This observation suggests a number of implications regarding both the Aβ accumulation itself and the dysregulation of APP-mediated signaling cascades. First of all, pre- and postsynaptic secretion of Aβ () can lead to its accumulation, oligomerization and impaired synaptic plasticity (). The positive feedback loop between Aβ and APP may serve as a signal amplifier in active synapses and increase the risk of Aβ aggregation in synapses that overproduced it. In turn, it is known that, being accumulated in neuronal terminals, APP affects vesicle coupling to kinesin-I, reducing axonal transport (). Thus, the Aβ-induced accumulation of APP possibly reduces the efficiency of kinesin-I-mediated axonal transport.
It is important to denote the pattern of Aβ42-induced APP accumulation. According to our data, the total APP content in cells is increased after 30 min of Aβ42 exposure, followed by a steady relocation to neurites. The increase of APP level in neurites develops over time and indicates alterations in APP trafficking.
Earlier, we demonstrated that incubation of SH-SY5Y cells with 100 nM Aβ42 results in rapid (within 30 min) activation of Na,K-ATPase-associated Src kinase via Aβ42 binding to Na,K-ATPase () and does not change Na,K-ATPase activity. We hypothesized that Src kinase may be involved in the regulation of APP trafficking (). This hypothesis was confirmed using a Src kinase inhibitor, which completely prevented Аβ-mediated upregulation of APP (Figure 2A). Thus, we assert the following sequence of events that form the positive feedback loop (Figure 4). First, binding of Аβ to Na,K-ATPase activates the Na,K-ATPase-associated Src kinase. In turn, Src kinase causes an increase in APP levels and its transport into neurites. It is likely that self-amplification of Aβ synthesis by the proposed mechanism serves as one of the key events in the pathogenesis of Alzheimer’s disease and explains the exponential pattern of its development ().
FIGURE 4
It should also be noted that, apart from a positive one, a negative feedback loop is also possible. In particular, Src kinase can activate phospholipase C, enhancing α-secretase activity involved in APP cleavage via the non-amyloidogenic pathway (). Thus, it is possible that activation of Src kinase by Aβ enhances APP level in cells, simultaneously increasing the contribution of the non-amyloid pathway to its proteolysis and preventing beta-amyloid from further excessive formation. On the other hand, the effect of Src kinase on APP may also turn out to be indirect. Namely, the phosphorylation of Src kinase by trafficking adapter Mint leads to APP accumulation in the trans-Golgi network, which impairs its transport through dendrites to synaptic terminals (). However, in our case, conversely, the level of APP in neurites is increased (Figure 1), hence another regulatory pathway can be assumed.
One could also suppose that one of the possible indirect ways in which Src kinase affects APP is via alterations of the redox status of cells. In particular, this could be caused by Аβ-mediated reduction in ROS and reduced glutathione (GSH) levels that occurs after 30 min of incubation in SH-SY5Y cells, as we have shown in (). However, inhibition of Src kinase exerted no effect on the Аβ-mediated reduction of GSH, which proves the independence of these effects (Figure 2E).
Since Src kinase activation is mediated by the binding of Aβ42 to Na,K-ATPase, which also acts as the receptor for cardiotonic steroids, we hypothesized that ouabain may influence the positive feedback loop we found. This hypothesis was confirmed: at a concentration of 100 nM, ouabain prevents Aβ42-induced activation of Src kinase and increase in APP levels, which makes it a promising CTS for preventing Aβ42-induced APP growth.
Earlier, the possibility of using CTS as part of the complex therapy of Alzheimer’s disease has been evaluated (; ; ; ). It was demonstrated that ouabain and digoxin, another cardiotonic steroid, can prevent cytotoxic effects in neurons due to inhibition of tau protein synthesis. This process is mediated by miR-132, one of the key neuroprotective miRNAs that is suppressed in Alzheimer’s disease (). Moreover, ouabain is able to reduce microglial neuroinflammation in murine models of Alzheimer’s disease (). Although the data obtained in mice are difficult to extrapolate to humans due to the presence of a ouabain-resistant Na,K-ATPase isoform in rodents (), our data support the idea of considering ouabain as a possible addition to Alzheimer’s disease therapy. It is ouabain that can offset the effect of Aβ, thereby preventing the development of a feedback loop between APP and Aβ and, as a result, reducing the dramatic increase in beta-amyloid in Alzheimer’s disease. Our findings demonstrate the possibility of diminished beta-amyloid-induced effects not only by regulating the activity of microglia (), but also by direct action of ouabain on neuronal cells. Remarkably, 100 nM ouabain does not inhibit Na,K-ATPase and does not affect the levels of sodium and potassium in SH-SY5Y cells after 30 min of incubation (). Thus, observed effect of ouabain on Src kinase activation and beta-amyloid-induced changes in APP levels is not associated with Na,K-ATPase inhibition. Further, since ouabain binding to Na,K-ATPase does not prevent amyloid binding (), it can be concluded that ouabain and Aβ are likely not to share the same binding site. One can suggest that ouabain prevents the signaling effects of beta-amyloid that are mediated by conformational changes of Na,K-ATPase ().
Notably, ouabain is detectable in cerebrospinal fluid at higher concentrations than in plasma (). Endogenous ouabain is now recognized not only as a centrally acting hormone but also as a paracrine neurohormone locally produced in the CNS, likely by the hypothalamus (; ). The levels of endogenous CTSs may vary under pathological conditions (). In a murine model of AD, marinobufagenin levels are shown to be decreased. Administration of exogenous marinobufagenin has been demonstrated to reduce neuroinflammation and lower IL-6 levels (). Despite the limited knowledge regarding CTS levels in AD patients, we hypothesize a decline in endogenous CTS levels in AD. This assumption is supported by previous observations indicating that the hypothalamus, a primary source of endogenous CTSs in the brain, is suppressed in AD. Particularly, levels of sex hormones were decreased in murine AD models (). Our data on ouabain modulation of beta-amyloid-induced alterations in APP levels and trafficking suggest its key regulatory role in beta-amyloid signaling. In this context, restoring physiological levels of CTSs could potentially inhibit AD progression. The administration of exogenous ouabain could restore ouabain levels to physiologically normal without inhibiting Na,K-ATPase, but rather slowing the accelerated formation of APP.
To sum up, the data suggest that Aβ activates Src kinase by binding to Na,K-ATPase, causing an increase in the APP level and its relocation to neurites in SH-SY5Y cells. This can lead to an even greater increase in beta-amyloid levels due to APP processing and a feedback loop. Specific Na,K-ATPase ligand, cardiotonic steroid ouabain, prevents impact of beta-amyloid on Src kinase and APP, which makes it a potential therapeutics against Alzheimer’s disease.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Author contributions
IP: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review and editing. DL: Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing. FF: Investigation, Writing – review and editing. OL: Investigation, Methodology, Validation, Writing – review and editing. VM: Conceptualization, Project administration, Writing – original draft, Writing – review and editing. MS: Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing. AM: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This research was funded by Russian Science Foundation grant #19-74-30007.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1665715/full#supplementary-material
References
1
AdzhubeiA. A.TolstovaA. P.StrelkovaM. A.MitkevichV. A.PetrushankoI. Y.MakarovA. A. (2022). Interaction interface of Aβ42 with human Na,K-ATPase studied by MD and ITC and inhibitor screening by MD. Biomedicines10 (7), 1663. 10.3390/biomedicines10071663
2
BagrovA. Y.ShapiroJ. I.FedorovaO. V. (2009). Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol. Rev.61 (1), 9–38. 10.1124/pr.108.000711
3
BarykinE. P.PetrushankoI. Y.KozinS. A.TeleginG. B.ChernovA. S.LopinaO. D.et al (2018). Phosphorylation of the amyloid-beta peptide inhibits zinc-dependent aggregation, prevents Na,K-ATPase inhibition, and reduces cerebral plaque deposition. Front. Mol. Neurosci.11, 302. 10.3389/fnmol.2018.00302
4
BurrinhaT.Guimas AlmeidaC. (2022). Aging impact on amyloid precursor protein neuronal trafficking. Curr. Opin. Neurobiol.73, 102524. 10.1016/j.conb.2022.102524
5
BurrinhaT.MartinssonI.GomesR.TerrassoA. P.GourasG. K.AlmeidaC. G. (2021). Upregulation of APP endocytosis by neuronal aging drives amyloid-dependent synapse loss. J. Cell Sci.134 (9), jcs255752. 10.1242/jcs.255752
6
DickeyC. A.GordonM. N.WilcockD. M.HerberD. L.FreemanM. J.MorganD. (2005). Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci.6, 7. 10.1186/1471-2202-6-7
7
DicksonD. W. (1997). The pathogenesis of senile plaques. Exp. Neurol.56 (4), 321–339. 10.1097/00005072-199704000-00001
8
DunningC. J. R.BlackH. L.AndrewsK. L.DavenportE. C.ConboyM.ChawlaS.et al (2016). Multisite tyrosine phosphorylation of the N-terminus of Mint1/X11α by src kinase regulates the trafficking of amyloid precursor protein. J. Neurochem.137 (4), 518–527. 10.1111/jnc.13571
9
DvelaM.RosenH.Ben-AmiH. C.LichtsteinD. (2012). Endogenous ouabain regulates cell viability. Am. J. Physiol. Cell. Physiol.302 (2), 442–452. 10.1152/ajpcell.00336.2011
10
ErdoganM. A.KirazlarM.YigitturkG.ErbasO. (2022). Digoxin exhibits neuroprotective properties in a rat model of dementia. Res.47 (5), 1290–1298. 10.1007/s11064-022-03528-w
11
FedorovaO. V.ZahariadisE.McDevittR.GrigorovaY. N.WeiW.ZernetkinaV. I.et al (2020). Steroidal inhibitor of Na/K‐ATPase marinobufagenin in a mouse model of Alzheimer’s disease: biomarkers (non‐neuroimaging)/novel biomarkers. Alzheimers Dement.16, e046617. 10.1002/alz.046617
12
HalperínJ.SchaefferR.GalvezL.MalavéS. (1983). Ouabain-like activity in human cerebrospinal fluid. Proc. Natl. Acad. Sci.80 (19), 6101–6104. 10.1073/pnas.80.19.6101
13
Jarosz-GriffithsH. H.NobleE.RushworthJ. V.HooperN. M. (2016). Amyloid-β receptors: the good, the bad, and the prion protein. J. Biol. Chem.291 (7), 3174–3183. 10.1074/jbc.R115.702704
14
JuckerM.WalkerL. C. (2013). Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature501 (7465), 45–51. 10.1038/nature12481
15
KlimanovaE. A.PetrushankoI. Y.MitkevichV. A.AnashkinaA. A.OrlovS. N.MakarovA. A.et al (2015). Binding of ouabain and marinobufagenin leads to different structural changes in Na,K-ATPase and depends on the enzyme conformation. FEBS Lett.589, 2668–2674. 19 Pt B. P. 10.1016/j.febslet.2015.08.011
16
KoinumaS.ShimozawaN.YasutomiY.KimuraN. (2021). Aging induces abnormal accumulation of Aβ in extracellular vesicle And/Or intraluminal membrane vesicle-rich fractions in nonhuman primate brain. Aging106, 268–281. 10.1016/j.neurobiolaging.2021.06.022
17
KreutzF.SchererE. B.FerreiraA. G. K.PetryF. D. S.PereiraC. L.SantanaF.et al (2013). Alterations on Na+,K+-ATPase and acetylcholinesterase activities induced by amyloid-β peptide in rat brain and GM1 ganglioside neuroprotective action//neurochem. Res38 (11), 2342–2350. 10.1007/s11064-013-1145-6
18
KulikovA.EvaA.KirchU.BoldyrevA.Scheiner-BobisG. (2007). Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim. Biophys. Acta BBA - Biomembr.1768 (7), 1691–1702. 10.1016/j.bbamem.2007.04.012
19
LaneC. A.HardyJ.SchottJ. M. (2018). Alzheimer's disease. J. Neurol.25 (1), 59–70. 10.1111/ene.13439
20
LeenenF. H. H.BlausteinM. P.HamlynJ. M. (2017). Update on angiotensin II: new endocrine connections between the brain, adrenal glands and the cardiovascular system. Endocr. Connect.6 (7), R131–R145. 10.1530/EC-17-0161
21
LiuJ.XieZ. (2010). The sodium pump and cardiotonic steroids-induced signal transduction protein kinases and calcium-signaling microdomain in regulation of transporter trafficking. Biochim. Biophys. Acta BBA - Mol. Basis Dis., 1802. 10.1016/j.bbadis.2010.01.013
22
MaC.HongF.YangS. (2022). Amyloidosis in alzheimer’s disease: Pathogeny, etiology, and related therapeutic directions. Molecules27 (4), 1210. 10.3390/molecules27041210
23
MarksS. M.LockhartS. N.BakerS. L.JagustW. J. (2017). Tau and β-Amyloid are associated with medial temporal lobe structure, function, and memory encoding in normal aging. J. Neurosci.37 (12), 3192–3201. 10.1523/JNEUROSCI.3769-16.2017
24
MüllerU. C.DellerT.KorteM. (2017). Not just amyloid: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci.18 (5), 281–298. 10.1038/nrn.2017.29
25
NguyenL. D.WeiZ.SilvaM. C.Barberán-SolerS.ZhangJ.RabinovskyR.et al (2023). Small molecule regulators of microRNAs identified by high-throughput screen coupled with high-throughput sequencing. Nat. Commun.14, 7575. 10.1038/s41467-023-43293-0
26
NiederstE. D.ReynaS. M.GoldsteinL. S. B. (2015). Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing. Mol. Biol. Cell.26 (2), 205–217. 10.1091/mbc.E14-06-1049
27
OrlovS. N.TverskoiA. M.SidorenkoS. V.SmolyaninovaL. V.LopinaO. D.DulinN. O.et al (2021). K-ATPase as a target for endogenous cardiotonic steroids: what’s the evidence?. Genes Dis.8 (3), 259–271. 10.1016/j.gendis.2020.01.008
28
OrobetsK. S.KaramyshevA. L. (2023). Amyloid precursor protein and alzheimer’s disease. Int. J. Mol. Sci.24 (19), 14794. 10.3390/ijms241914794
29
PerdigãoC.BarataM. A.AraújoM. N.MirfakharF. S.CastanheiraJ.Guimas AlmeidaC. (2020). Intracellular trafficking mechanisms of synaptic dysfunction in alzheimer’s disease. Front. Cell. Neurosci.14, 72. 10.3389/fncel.2020.00072
30
PetrushankoI. Y.MitkevichV. A.AnashkinaA. A.AdzhubeiA. A.BurnyshevaK. M.LakuninaV. A.et al (2016). Direct interaction of beta-amyloid with Na,K-ATPase as a putative regulator of the enzyme function. Sci. Rep.6, 27738. 10.1038/srep27738
31
PetrushankoI. Y.TverskoiA. M.BarykinE. P.PetrovskayaA. V.StrelkovaM. A.LeonovaO. G.et al (2022). Na,K-ATPase acts as a beta-amyloid receptor triggering src kinase activation. Cells11 (17), 2753. 10.3390/cells11172753
32
PimenovaA. A.ThathiahA.De StrooperB.TesseurI. (2014). Regulation of amyloid precursor protein processing by serotonin signaling. PloS One9 (1), e87014. 10.1371/journal.pone.0087014
33
PoluektovY. M.LopinaO. D.StrelkovaM. A.KuleshovaI. D.MakarovA. A.PetrushankoI. Y. (2025). Mechanisms mediating effects of cardiotonic steroids in Mammalian blood cells. Front. Pharmacol.16, 1520927. 10.3389/fphar.2025.1520927
34
PrusinerS. B. (2012). Cell biology. A unifying role for prions in neurodegenerative diseases. Science336, 1511–1513. 10.1126/science.1222951
35
QiG.TangH.GongP.LiuY.HeC.HuJ.et al (2024). Sex-specific hypothalamic neuropathology and glucose metabolism in an amyloidosis transgenic mouse model of Alzheimer’s disease. Cell Biosci.14 (1), 120. 10.1186/s13578-024-01295-5
36
SchatzmannH. J. (1953). cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane. Physiol. Pharmacol. Acta.11 (4), 346–354.
37
ShinH. K.RyuB. J.ChoiS.-W.KimS. H.LeeK. (2015). Inactivation of src-to-ezrin pathway: a possible mechanism in the ouabain-mediated inhibition of A549 cell migration. Biomed. Res. Int.2015, 537136. 10.1155/2015/537136
38
SongH.-L.DemirevA. V.KimN.-Y.KimD.-H.YoonS.-Y. (2019). Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer’s disease. Mol. Cell. Neurosci.95, 13–24. 10.1016/j.mcn.2018.12.007
39
StokinG. B.LilloC.FalzoneT. L.BruschR. G.RockensteinE.MountS. L.et al (2005). Axonopathy and transport deficits early in the pathogenesis of alzheimer’s disease. Science307 (5713), 1282–1288. 10.1126/science.1105681
40
SunJ.RoyS. (2018). The physical approximation of APP and BACE-1: a key event in alzheimer’s disease pathogenesis. Dev. Neurobiol.78 (3), 340–347. 10.1002/dneu.22556
41
WaltonJ. R.WangM.-X. (2009). APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer’s disease. J. Inorg. Biochem.103 (11), 1548–1554. 10.1016/j.jinorgbio.2009.07.027
42
WangD.LiuJ.ZhuQ.WeiX.ZhangX.ChenQ.et al (2024). Ouabain ameliorates alzheimer’s disease-associated neuropathology and cognitive impairment in FAD4T mice. Nutrients16 (20), 3558. 10.3390/nu16203558
43
WeidemannH.SalomonN.Avnit-SagiT.WeidenfeldJ.RosenH.LichtsteinD. (2004). Diverse effects of stress and additional adrenocorticotropic hormone on digitalis-like compounds in normal and nude mice. J. Neuroendocrinol.16 (5), 458–463. 10.1111/j.1365-2826.2004.01181.x
44
WelikovitchL. A.DoC. S.MaglóczkyZ.SzocsicsP.LőkeJ.FreundT.et al (2018). Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex. Acta Neuropathol. (Berl.).136 (6), 901–917. 10.1007/s00401-018-1922-z
45
WuJ.AkkuratovE. E.BaiY.GaskillC. M.AskariA.LiuL. (2013). Cell signaling associated with Na(+)/K(+)-ATPase: activation of phosphatidylinositide 3-kinase IA/Akt by ouabain is independent of src. Biochemistry52 (50), 9059–9067. 10.1021/bi4011804
46
ZhangL.-N.SunY.-J.PanS.LiJ.-X.QuY.-E.LiY.et al (2013). Na+-K+-ATPase, a potent neuroprotective modulator against alzheimer disease//fundam. Clin. Pharmacol.27 (1), 96–103. 10.1111/fcp.12000
Summary
Keywords
beta-amyloid, APP, Src kinase, ouabain, APP trafficking, Na,K-ATPase
Citation
Petrushanko IY, Lisitskii DR, Filonov FA, Leonova OG, Mitkevich VA, Strelkova MA and Makarov AA (2025) Beta-amyloid influences the content and trafficking of beta-amyloid precursor protein via Na,K-ATPase-Src kinase positive feedback loop. Front. Pharmacol. 16:1665715. doi: 10.3389/fphar.2025.1665715
Received
14 July 2025
Accepted
08 September 2025
Published
24 September 2025
Volume
16 - 2025
Edited by
Alexei Bagrov, Padakonn Pharma, Estonia
Reviewed by
Rubén G. Contreras, National Polytechnic Institute of Mexico (CINVESTAV), Mexico
Irina Romanova, Sechenov Institute of Evolutionary Physiology and Biochemistry, Russia
Updates
Copyright
© 2025 Petrushanko, Lisitskii, Filonov, Leonova, Mitkevich, Strelkova and Makarov.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Irina Yu Petrushanko, irina-pva@mail.ru; Alexander A. Makarov, aamakarov@eimb.ru
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.